Literature DB >> 15617532

Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease.

Egemen Savaskan1, Mohammed A Ayoub, Rivka Ravid, Debora Angeloni, Franco Fraschini, Fides Meier, Anne Eckert, Franz Müller-Spahn, Ralf Jockers.   

Abstract

The aim of the present study was to identify the distribution of the second melatonin receptor (MT2) in the human hippocampus of elderly controls and Alzheimer's disease (AD) patients. This is the first report of immunohistochemical MT2 localization in the human hippocampus both in control and AD cases. The specificity of the MT2 antibody was ascertained by fluorescence microscopy using the anti-MT2 antibody in HEK 293 cells expressing recombinant MT2, in immunoblot experiments on membranes from MT2 expressing cells, and, finally, by immunoprecipitation experiments of the native MT2. MT2 immunoreactivity was studied in the hippocampus of 16 elderly control and 16 AD cases. In controls, MT2 was localized in pyramidal neurons of the hippocampal subfields CA1-4 and in some granular neurons of the stratum granulosum. The overall intensity of the MT2 staining was distinctly decreased in AD cases. The results indicate that MT2 may be involved in mediating the effects of melatonin in the human hippocampus, and this mechanism may be heavily impaired in AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15617532     DOI: 10.1111/j.1600-079X.2004.00169.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  61 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

3.  MT2 melatonin receptor immunoreactivity in neurons is very high in the aged hippocampal formation in gerbils.

Authors:  Choong Hyun Lee; Jung Hoon Choi; Ki-Yeon Yoo; Ok Kyu Park; In Koo Hwang; Sang Guan You; Boo-Yong Lee; Il-Jun Kang; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2009-09-02       Impact factor: 5.046

4.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

5.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

6.  Genetic deletion of the MT1 or MT2 melatonin receptors abrogates methamphetamine-induced reward in C3H/HeN mice.

Authors:  Shannon J Clough; Anthony J Hutchinson; Randall L Hudson; Margarita L Dubocovich
Journal:  Physiol Behav       Date:  2014-05-09

7.  Melatonin improves memory acquisition under stress independent of stress hormone release.

Authors:  Ulrike Rimmele; Maria Spillmann; Carmen Bärtschi; Oliver T Wolf; Cora S Weber; Ulrike Ehlert; Petra H Wirtz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

8.  The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors.

Authors:  Arabinda Das; Misty McDowell; Matthew J Pava; Joshua A Smith; Russel J Reiter; John J Woodward; Abhay K Varma; Swapan K Ray; Naren L Banik
Journal:  J Pineal Res       Date:  2010-01-17       Impact factor: 13.007

9.  Drug- and region-specific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT(1) and MT(2) receptor mRNA in the mouse brain.

Authors:  Marta Imbesi; Tolga Uz; Sevim Yildiz; Ahmet D Arslan; Hari Manev
Journal:  Int J Neuroprot Neuroregener       Date:  2006

10.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.